hydroxychloroquine has been researched along with Seizures in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of this systematic review is to assess the published literature for seizure risk with chloroquine or hydroxychloroquine therapy in persons with and without epilepsy." | 7.96 | Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy. ( Houston, T; Pati, S, 2020) |
| "The goal of this systematic review is to assess the published literature for seizure risk with chloroquine or hydroxychloroquine therapy in persons with and without epilepsy." | 3.96 | Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy. ( Houston, T; Pati, S, 2020) |
| "Acute cerebellar ataxia is a rare primary manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE)." | 2.72 | Cerebellar ataxia as a primary manifestation of neuropsychiatric systemic lupus erythematosus. ( Fernandez, MLL; Reyes, NGD; Sy, MCC; Zamora, GT, 2021) |
| "Her quadriparesis was found to be secondary to biopsy-proven hydroxychloroquine-induced myopathy with concomitant inflammatory myopathy." | 2.55 | Antimalarial myopathy in a systemic lupus erythematosus patient with quadriparesis and seizures: a case-based review. ( Bucknor, MD; Chaganti, RK; Jafri, K; Nolan, AL; Patterson, S; Wysham, KD; Zahed, H, 2017) |
| "We report on a case of a 17-year-old female with systemic lupus erythematosus (SLE), with a clinical history of complex partial seizure, who developed a tonicoclonic crisis after receiving hydroxychloroquine for 2 weeks at a dosage of 200 mg/day (5 mg/kg)." | 1.31 | Hydroxychloroquine-induced seizure in a patient with systemic lupus erythematosus. ( Cappelli, M; Danieli, MG; Fraticelli, P; Malcangi, G; Palmieri, C, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Afshar, H | 1 |
| Yassin, Z | 1 |
| Kalantari, S | 1 |
| Aloosh, O | 1 |
| Lotfi, T | 1 |
| Moghaddasi, M | 1 |
| Sadeghipour, A | 1 |
| Emamikhah, M | 1 |
| Kadono, Y | 1 |
| Nakamura, Y | 1 |
| Ogawa, Y | 1 |
| Yamamoto, S | 1 |
| Kajikawa, R | 1 |
| Nakajima, Y | 1 |
| Matsumoto, M | 1 |
| Kishima, H | 1 |
| Pati, S | 1 |
| Houston, T | 1 |
| Sy, MCC | 1 |
| Reyes, NGD | 1 |
| Zamora, GT | 1 |
| Fernandez, MLL | 1 |
| Jafri, K | 1 |
| Zahed, H | 1 |
| Wysham, KD | 1 |
| Patterson, S | 1 |
| Nolan, AL | 1 |
| Bucknor, MD | 1 |
| Chaganti, RK | 1 |
| ROSENBERG, FJ | 1 |
| BOTTIROLI, JA | 1 |
| Malcangi, G | 1 |
| Fraticelli, P | 1 |
| Palmieri, C | 1 |
| Cappelli, M | 1 |
| Danieli, MG | 1 |
2 reviews available for hydroxychloroquine and Seizures
| Article | Year |
|---|---|
Cerebellar ataxia as a primary manifestation of neuropsychiatric systemic lupus erythematosus.
Topics: Adult; Anti-Inflammatory Agents; Antimalarials; Cerebellar Ataxia; Female; Gait Analysis; Headache; | 2021 |
Antimalarial myopathy in a systemic lupus erythematosus patient with quadriparesis and seizures: a case-based review.
Topics: Adult; Antimalarials; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Muscular Di | 2017 |
5 other studies available for hydroxychloroquine and Seizures
| Article | Year |
|---|---|
Evolution and resolution of brain involvement associated with SARS- CoV2 infection: A close Clinical - Paraclinical follow up study of a case.
Topics: Adult; Anti-Bacterial Agents; Anticonvulsants; Atazanavir Sulfate; Betacoronavirus; Brain; Conscious | 2020 |
A case of COVID-19 infection presenting with a seizure following severe brain edema.
Topics: Adult; Anti-Bacterial Agents; Anticoagulants; Anticonvulsants; Azithromycin; Betacoronavirus; Brain | 2020 |
Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy.
Topics: Adolescent; Adult; Aged; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Dr | 2020 |
ANTIMALARIALS AND OTHER ANTICONVULSANT DRUGS: PREDICTIVE VALIDITY OF LABORATORY TESTS.
Topics: Animals; Anticonvulsants; Antimalarials; Chloroquine; Electric Stimulation; Hydroxychloroquine; Mice | 1964 |
Hydroxychloroquine-induced seizure in a patient with systemic lupus erythematosus.
Topics: Adolescent; Antirheumatic Agents; Contraindications; Female; Humans; Hydroxychloroquine; Lupus Eryth | 2000 |